Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triptorelin for Ovary Protection in Childhood Onset Lupus
NCT00124514Phase 2Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Jun 2003
- Primary completion
- Mar 2014
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of triptorelin in systemic lupus erythematosus (SLE) (5 arms), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Dose of Triptorelin for Ovarian Suppression at 24 weeks. Started Jun 2003; status: completed.
02
Drugs
triptorelin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00124514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124514.